Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib Plus Chemotherapy in NSCLC With EGFR Exon 20 Insertion Mutations
NCT05973773Phase 3Active, not recruiting
- Sponsor
- Taiho Oncology
- Start
- Dec 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Taiho Oncology. Primary endpoints: Treatment-Emergent Adverse Events at 5 years, Progression-Free Survival at 5 years and 1 more. Started Dec 2023; status: active, not recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05973773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05973773.